Common Stock
- Symbol
- CNTX
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 7.01, 8.01, 9.01 · 8-K
Context Therapeutics Inc.
CNTXNASDAQEQUITYCurrent
Regulation FD Disclosure · Other Events
Item 7.01. Regulation FD Disclosure. On June 15, 2026, Context Therapeutics Inc. (the “Company”) posted an updated corporate presentation on its website at www.contexttherapeutics.com. A copy of the presentation is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference into this Item 7.01.…
Registered securities in this filing
Context Therapeutics Inc. · 8-K · Filed 2026-06-15
Disclosure sections
Item 7.01Item 7.01 - Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure.
On June 15, 2026, Context Therapeutics Inc. (the “Company”) posted an updated corporate presentation on its website at www.contexttherapeutics.com. A copy of the presentation is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference into this Item 7.01.
The information in this Item 7.01, and Exhibit 99.1 attached hereto, are being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.
Item 8.01Item 8.01 - Other Events
Item 8.01. Other Events.
On June 15, 2026, the Company issued a press release announcing positive interim efficacy and safety results from its ongoing Phase 1 clinical trial for CTIM-76, the Company’s investigational Claudin 6 x CD3 T cell engaging bispecific antibody. A copy of the press release is filed as Exhibit 99.2 to this Current Report on Form 8-K and incorporated herein by reference into this Item 8.01.
On June 15, 2026, the Company also hosted a conference call to discuss the interim CTIM-76 Phase 1 clinical trial data. A copy of the presentation used during the conference call is filed as Exhibit 99.3 to this Current Report on Form 8-K and incorporated herein by reference into this Item 8.01.